SecBot SecBot
8-K ·Filed Jul 13, 2026

OABIW

OmniAb, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago SEC0001846253-26-000042
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine C-suite addition with no immediate trading signal. The stock option grant of 800,000 shares represents potential future dilution, but it is standard equity compensation. Monitor the next 10-Q for any operational updates under the new COO.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
OABIW ▲ +382.08% at T+60d
NEUTRAL call +382.08% · α vs SPY +378.08% · entry $0.0809 → $0.3900
Entry = T+0 close
Jul 13, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.36%
$0.0809
settled 4mo ago
T+5d
-1.98%
call -1.98% · α -1.19%
$0.0793
settled 3mo ago
T+20d
-1.11%
call -1.11% · α -4.30%
$0.0800
settled 3mo ago
T+60d
+382.08%
call +382.08% · α +378.08%
$0.3900
settled 21d ago

Price Chart

Loading chart...

Executive Summary

OmniAb appointed Amechi Nwachuku as Chief Operating Officer effective July 13, 2026. The appointment is a routine addition to the management team and does not signal any material change in financial condition or operations.

Key Facts

  • Amechi Nwachuku appointed as COO, effective July 13, 2026
  • Mr. Nwachuku is a 51-year-old global life sciences executive with prior roles at Thermo Fisher, SCIEX, Beckman Coulter, J&J, and Bayer
  • Initial annual base salary of $445,000; target annual bonus of 45% of base salary ($200,250) prorated for 2026; $20,000 signing bonus
  • Granted options to purchase 800,000 shares of common stock, effective August 1, 2026, under the 2022 Incentive Award Plan, vesting over 4 years
  • Eligible for standard severance and change-in-control severance benefits per company plans
  • No departure of any officer; no other executive changes reported

Financial Impact

Compensation commitments including $445,000 salary, $200,250 target bonus, $20,000 signing bonus, and 800,000 share stock option grant. Immaterial relative to company operations.

Risk Factors

  • Standard dilution from 800,000 share options if exercised; vesting over 4 years minimizes near-term impact
  • No departure or performance concerns flagged — risk of disruption is low

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001846253-26-000042
Document: 0001846253-26-000042-index-headers.html0001846253-26-000042
Document: 0001846253-26-000042-index.html0001846253-26-000042
Document: 0001846253-26-000042.txt0001846253-26-000042
5 reports for OABIW
Performance horizon
Filters
Rows
Reports for OABIW — sortable, filterable
TypeNow
Jul 13, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$0.0809 $0.0800▼ −1.11%▼ −4.30%—
Apr 7, 2026
28w ago
144
NEUTRAL ★ 3/10
$0.0900 $0.0900· 0.00%▼ −8.54%—
Apr 7, 2026
28w ago
144
NEUTRAL ★ 3/10
$0.0900 $0.0900· 0.00%▼ −8.54%—
Apr 7, 2026
28w ago
144
NEUTRAL ★ 3/10
$0.0900 $0.0900· 0.00%▼ −8.54%—
Mar 4, 2026
33w ago
8-K
MIXED ★ 6/10
—awaiting T+20——
Showing 5 of 5

US Market Status

Market Closed — Opens Wed (13h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026